Ad is loading...
MENU

ICCC Stock ImmuCell (ICCC, $3.53) Moving Average Convergence Divergence (MACD) Histogram turned negative on November 13, 2024

A.I.dvisor
at Tickeron.com
Loading...
ICCC - ImmuCell Corp
MACD signal
Bearish Trend
Odds of DOWN Trend
Tickeron
MACD signal
Price: $3.53
Daily change: -$0.12 (-3.29%)
Daily volume: 10.9K
Industry: Biotechnology
This is a Bearish indicator signaling ICCC's price could decline from here. Traders may explore shorting the stock or put options. A.I. dvisor identified 46 similar cases where ICCC's MACD histogram became negative, and of them led to successful outcomes. Odds of Success:

ICCC in downward trend: price dove below 50-day moving average on November 13, 2024

ICCC moved below its 50-day moving average on November 13, 2024 date and that indicates a change from an upward trend to a downward trend. In of 64 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICCC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 52 cases where ICCC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 15, 2024. You may want to consider a long position or call options on ICCC as a result. In of 115 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ICCC just turned positive on November 14, 2024. Looking at past instances where ICCC's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ICCC advanced for three days, in of 224 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ICCC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.206) is normal, around the industry mean (14.849). P/E Ratio (0.000) is within average values for comparable stocks, (95.928). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). ICCC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (1.207) is also within normal values, averaging (211.128).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ICCC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of products for cattle health

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
56 Evergreen Drive
Phone
+1 207 878-2770
Employees
79
Web
https://www.immucell.com